This review highlights the difficulty in differentiating low-risk from high-risk IPMNs and underscores the significance of biomarkers such as KRAS and GNAS mutations, which are directly linked to IPMN progression. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.